by TractManager | Nov 27, 2019 | News
These FDA developments came in this week:FDA Approves System for In-Office Tympanostomy TubesOn November 25, 2019, the Food and Drug Administration (FDA) granted approval for the TULA system (Tusker Medical), the first system that allows insertion of tympanostomy...
by TractManager | Nov 26, 2019 | Emerging Technology Report
Oxbryta (voxelotor) is a first-in-class oral hemoglobin oxygen affinity modulator that is believed to target and bind to the N-terminal valine of the alpha chain of hemoglobin S (HbS). This improves hemoglobin oxygen affinity and consequently inhibits HbS...
by TractManager | Nov 26, 2019 | News
On November 25, 2019, the Food and Drug Administration (FDA) approved Oxbryta (voxelotor; Global Blood Therapeutics Inc.), a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients aged 12 years...
by TractManager | Nov 26, 2019 | Emerging Technology Report
Oxbryta (voxelotor) is a first-in-class oral hemoglobin oxygen affinity modulator that is believed to target and bind to the N-terminal valine of the alpha chain of hemoglobin S (HbS). This improves hemoglobin oxygen affinity and consequently inhibits HbS...
by TractManager | Nov 25, 2019 | Emerging Technology Report
Caplacizumab is a subcutaneously injected biologic agent intended for use as an adjunct to standard care for acquired thrombotic thrombocytopenic purpura. It is a bivalent single-domain anti-von Willebrand factor (VWF) nanobody that inhibits the binding of VWF to...
Recent Comments